Schering Aktiengesellschaft

Novartis Ag

Other

Shering Ag

Schering Aktiengeseellschaft

Scnering Aktiengesellschaft

Dieter Seidelmann

Andreas Huth

Ralph Schmiechen

Dieter Rahtz

Herbert H Schneider

David N Stephens

Mogens Engelstoft

Lechoslaw Turski

Helmut Biere

Karl-Heinz Thierauch

Andreas Menrad

Martin Kruger

Claus T Braestrup

Martin Haberey

Eckhard Ottow

Wolfgang Kehr

Pascal Furet

Paul William Manley

Guido Bold

John Bondo Hansen

Jeanette Marjorie Wood

Erling N Petersen

Stefano Ferrari

Karl-Heinz Altmann

Leif H Jensen

Martin Krueger

Jürgen Mestan

Dieter Palenschat

Martin Krüger

Tage Honore

Francesco Hofmann

Frank Watjen

Ulrich Eder

Orlin Petrov

Ralph Rohde

Gert Paschelke

Alexander Ernst

Peter Holscher

Peter A Loschmann

Frank Waetjen

Martin Kr&uuml;ger

Ingrid Schumann

Ilse Beetz

Bondo John Hansen

Jogen A Christensen

Rudolf Wiechert

Ulrich Speck

Bernd Muller

Gunter Neef

Roland Neuhaus

Werner Krause

Reinhard Horowski

Erich Klieger

Guenter Neef

Peter Blaszkiewicz

Jonathan Turner

Margrit Hillmann

Michael Schirner

Belinda Cole

John S Andrews

Helmut Schmiechen

J&uuml;rgen Mestan

Graham H Jones

Preben Olesen

Preben Olsen

Jose Brüggen

The invention relates to substituted anthranylalkyl and -cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis. 

Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors

The invention relates to anthranilic acid amides and the use thereof as medicaments for the treatment of diseases that are triggered by persistent angiogenesis, in addition to intermediate products in the production of anthranilic acid amides.

Anthranilic acid amides and the use thereof as medicaments

Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.

Ortho-substituted anthranilic acid amides and their use as medicaments

Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.

Anthranyl amides and their use as medicaments

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that Rcannot represent 2-phthalimidyl, and in case of Y=SOcannot represent 2,1,3-benzothiadiazol-4-yl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that Rcannot represent 2-phthalimidyl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

VEGF receptor tyrosine kinase inhibitors

The invention relates to substituted anthranylalkyl and cycloalkyl amides of general formula (I) and to their use as medicaments for treating diseases caused by persistent angiogenesis.

Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors

Described are compounds of formula (I), wherein W is O or S; X is NR ; Y is CR R &mdash;(CH )n wherein R and R are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S0 ; R is aryl; R is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R cannot represent 2-phthalimidyl, and in case of Y&equals;SO cannot represent 2,1,3-benzothiadiazol-4-yl; any of R , R , R and R , independently of the other, is H or a substituent other than hydrogen; and R and R , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

The disclosure relates to quinoxaline derivates of Formula I

Quinoxaline-carboxylic acid derivatives

Quinoxalinedione derivatives, their production and use in pharmaceutical

Quinoxaline dione derivatives, their production and their use in

Anellated .beta.-carbolines

The disclosure relates to quinoxaline derivatives of Formula I ##STR1## wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the disclosure, as well as their production and use in medicinal agents.

Quinoxaline-phosphonic acid derivatives

5- or 6-substituted .beta.-carboline-3-carboxylic acid esters of Formula I ##STR1## wherein R.sup.1 is hydrogen, nitrilo, halogen, lower alkyl or lower alkoxy, and

5- or 6-substituted .beta.-carboline-3-carboxylic acid esters

Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a triazine or benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Hetaryloxy-.beta.-carbolines, their production and use in pharmaceutical

Growing community of inventors

Berlin, Germany

Dieter Seidelmann